Read the correct leaflet
Use the leaflet for the prescribed presentation, not another brand containing a related molecule. EMA information for Wegovy describes common digestive effects, among others. Consult complete frequencies, warnings and precautions in current official information. A short website list cannot replace the leaflet.
Agree on what to do before difficulties occur
Ask whom to contact about troublesome effects, which signs need prompt advice and how other treatments should be managed in your situation. Severe or persistent abdominal pain, significant vomiting, difficulty staying hydrated or sudden vision changes warrant medical contact without waiting for the next appointment. For immediate danger, contact emergency services. These examples are not exhaustive.
Record without self-prescribing
Record the symptom, onset, progression and medicines taken, then share these with the clinician. Do not change quantities, combine products or substitute a medicine based on an online comment. Dietary advice and treatment adjustments belong within individual follow-up.
EXAMPLE / HOW TO USE IT
A note for your clinician
“Symptom began Tuesday, has persisted, affects meals and drinks; other treatments: list attached. What should I do?” A precise account assists assessment. Our template stays on your device and collects no health information.
Read the figure text
Read the correct leaflet: Use the leaflet for the prescribed presentation, not another brand containing a related molecule. · Agree on what to do before difficulties occur: Ask whom to contact about troublesome effects, which signs need prompt advice and how other treatments should be managed in your situation. · Record without self-prescribing: Record the symptom, onset, progression and medicines taken, then share these with the clinician.
Keep this checklist
- Read the exact leaflet.
- Agree on contacts and signs to monitor.
- Describe onset and symptom progression.
- Seek advice without changing treatment yourself.
Sources and limitations
- EMA — Wegovy indications and medicine information
- EMA — Ozempic authorisation and medicine information
- EMA — Mounjaro indications and medicine information
- EMA — current Wegovy product information
- EMA — NAION as a very rare semaglutide adverse effect, 2025
References consulted for this edition. Studies and documents retain their actual years. Educational examples and documentary procedures, not personal product trials.
